Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Pontevedra – page 2

65 clinical trials in Pontevedra, Spain. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Pontevedra at a glance
65
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

65 trials in Pontevedra

Open in trial search

Conjunctivitis allergic+3

Recruiting

Dermatophagoides farinae, Dermatophagoides pteronyssinus, and Lepidoglyphus destructor Immunotherapy for Allergic Rhinitis and Rhinoconjunctivitis in Patients With or Without Mild Asthma

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Allergen extracts
  • Sponsor:Inmunotek S.L.

Chronic obstructive pulmonary disease

Recruiting

A study to evaluate the efficacy and safety of depemokimab and salbutamol sulfate in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Conjunctivitis allergic+1

Recruiting

Study of the efficacy and safety of depigmented polymerized grass pollen extracts for patients with allergic rhinitis and controlled asthma.

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dactylis Glomerata Pollen Extract
  • Sponsor:LETI Pharma S.L.U.

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Dermatitis atopic

Recruiting

Study of GHZ339 for treatment of moderate to severe atopic dermatitis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:GHZ339
  • Sponsor:Novartis Pharma AG

Acute respiratory distress syndrome

Recruiting

Study of inhaled aprotinin for treatment of moderate to severe acute respiratory distress syndrome

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aprotinin
  • Sponsor:Fundacion Del Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion

Acute respiratory failure

Recruiting

Study on the Effects of Dexamethasone in Adults with Acute Respiratory Failure Due to Infections, Including COVID-19

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone Sodium Phosphate
  • Sponsor:Consorcio Centro De Investigacion Biomedica En Red

Pruritus

Recruiting

Study on the Effectiveness and Safety of Dupilumab for Adults with Chronic Itch of Unknown Cause

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Psoriasis

Recruiting

Study on Risankizumab for Children Aged 6-17 With Moderate to Severe Plaque Psoriasis After Completing Previous Study

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Meniere's disease

Recruiting

Study on Betahistine Dihydrochloride for Treating Adults with Menière's Disease

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Betahistine Dihydrochloride
  • Sponsor:Intas Pharmaceuticals Limited

Alcoholic liver disease

Recruiting

Study on the Safety and Effectiveness of GSK4532990 for Adults Aged 18-65 with Alcohol-Related Liver Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Pontevedra

What the registry says about research in the country

01 Infectious Diseases

Clinical studies focusing on tuberculosis treatments, including innovative approaches for both latent and active forms of the disease in special patient populations.

  • Pulmonary tuberculosis treatment optimization
  • Latent TB in kidney disease patients
  • Novel drug combinations

Research evaluating the effectiveness of various rifamycin-based regimens and high-dose antibiotic combinations.

02 Hepatology

Extensive research into liver diseases, particularly focusing on non-alcoholic steatohepatitis (NASH) and chronic hepatitis B treatments.

  • NASH therapy development
  • Chronic hepatitis B management
  • Liver fibrosis treatment

Multiple studies evaluating novel therapeutic approaches and combination treatments for liver conditions.

03 Dermatology & Immunology

Innovative research in inflammatory skin conditions and immune-mediated disorders, including studies on atopic dermatitis and urticaria.

  • Atopic dermatitis treatment
  • Chronic urticaria management
  • Hidradenitis suppurativa therapy

Investigation of new targeted therapies and dose optimization studies for various skin conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.